Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experienceYasuhiro Oki, Jason R. Westin, Yago Nieto et al.|British Journal of Haematology|2014Cited by 364
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C. Pinnix, Loretta J. Nastoupil, Jillian R. Gunther et al.|Blood Advances|2020Cited by 224
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphomaPaolo Strati, Sattva S. Neelapu, Sairah Ahmed et al.|Blood|2021Cited by 213
Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphomaPaolo Strati, Jason R. Westin, Sairah Ahmed et al.|Blood Advances|2020Cited by 195
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicityUri Greenbaum, Sairah Ahmed, Paolo Strati et al.|Blood Advances|2021Cited by 146